NCT02289209View on ClinicalTrials.gov

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 9, 2016

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2024

Conditions
Recurrent Head and Neck CancerCarcinoma, Squamous Cell of Head and Neck
Interventions
RADIATION

Reirradiation

Reirradiation 1.2 GY BID 5 days a week for 5 weeks.

DRUG

MK-3475

MK-3475 will be given at 200mg intravenous every 3 weeks starting day one of reirradiation and will be continued once every 3 weeks until 3 months post completion of reirradiation. Further continuation of MK-3475 will be determined by response evaluation at 3 months post completion of reirradiation

Trial Locations (4)

15232

UPMC Hillman Cancer Center, Pittsburgh

19111

Fox Chase Cancer Center, Philadelphia

21201

Univeristy of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore

21287

Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dan Zandberg

OTHER

NCT02289209 - Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck | Biotech Hunter | Biotech Hunter